Application of B7H4 in preparation of endometrial cancer molecular typing reagent and system

Abstract

The invention relates to application of B7H4 in preparation of an endometrial cancer molecular typing reagent and system. The method comprises the following steps: firstly, screening out a POLE mutant by a sequencing method; detecting four kinds of mismatch repair proteins on a specimen without pathogenic mutation, and screening out a dMMR type; screening out a p53 mutant from a sample without dMMR by means of immunohistochemical detection of p53 protein; if the p53 mutation does not exist, determining that the p53 mutation is an NSMP type; and for specimens for interpreting the dMMR type and the NSMP type, detecting expression of protein B7H4 through immunohistochemistry, wherein B7H4 coloring in more than 1% of tumor cells is judged as a B7H4 expression type, and B7H4 non-expression types are judged in the rest. According to the invention, endometrial cancer is divided into a POLE mutant type, a B7H4 expression type, a B7H4 non-expression type and a p53 mutant type; and the improved molecular typing is still based on molecular pathology, has the characteristics of relative objectiveness, high repeatability and clinical feasibility of the existing molecular typing, but has higher predictive ability than the existing model, and is beneficial to avoiding excessive treatment and insufficient treatment.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of B7H4 in the preparation of endometrial cancer molecular typing reagents and systems. Background technique [0002] Endometrial cancer is a common malignant tumor of the female reproductive tract in my country, and the age of onset tends to be younger. In 2015, there were about 63,000 new cases of endometrial cancer in my country, and about 22,000 deaths. The treatment of endometrial cancer patients is based on surgery, and those with high risk of recurrence after surgery should be combined with adjuvant therapy such as chemotherapy and chemotherapy. The choice of postoperative adjuvant therapy is mainly based on surgical pathological results and surgical staging, including FIGO staging, histological type, degree of tumor differentiation, tumor grade, depth of tumor myometrial invasion, and lymphovascular space invasion (LVSI). Postoperative adjuvant therapy is base...

AI Technical Summary

Problems solved by technology

It can be seen that the current molecular classification can only distinguish a small number of patients with good prognosis from patients with very poor prognosis, and cannot predict the prognosis of most endometrial cancer patients.

Images